Related Experiment Video
Updated: Aug 17, 2026

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
Published on: September 21, 2017
Dopamine: receptors and clinical applications
Abstract:
Dopamine (DA) receptors have been divided into two subtypes: DA1 receptors which subserve vasodilation in renal, mesenteric, coronary, and cerebral vascular beds, and DA2 receptors which when activated cause inhibition of release of norepinephrine in sympathetic nerve endings. The subdivisions were made on the basis of differences in chemical structure and potency series of agonists and antagonists for the two receptor subtypes. Agonists and antagonists are now available which selectively act on DA1 or DA2 receptors. The clinical use of DA, DA pro-drugs, and selective DA agonists is discussed with particular emphasis on the treatment of congestive heart failure and hypertension. Finally, data are presented concerning possible relationships between peripheral DA1 and DA2 receptors and DA receptors classified in the central nervous system.
More Related Videos
Related Concept Videos
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Drugs Affecting Neurotransmitter Release or Uptake
Drugs Affecting Neurotransmitter Synthesis
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

